Regeneron, Bayer sales and marketing update

Germany’s Institute for Quality and Efficiency in Healthcare (IQWiG) said in a dossier assessment that it “cannot concede evidence of an additional benefit” for Eylea aflibercept from Bayer vs. Lucentis ranibizumab or grid laser therapy to treat visual impairment due to macular edema in branch retinal vein occlusion (BRVO). Bayer believes that ophthalmologists now consider grid laser therapy as a second-line treatment option, and thus the pharma only accepts ranibizumab as an appropriate comparator in the indication. The pharma added that there was no relevant direct or indirect data available to accurately compare Eylea to Lucentis in the indication. Bayer expects a final decision from Germany’s Federal Joint Committee (G-BA) on Eylea in the macular edema following BRVO indication in September. ...